UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
NEUROSCIENCE & CNS

Teva Pharmaceutical Industries

T

Teva Pharmaceutical Industries

Neuroscience & CNSTel Aviv, Israel
Visit Website

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is the world's largest generic medicines company, supplying roughly one in every six generic prescriptions filled in the United States and operating across more than 60 countries. Founded in Jerusalem in 1901, the Israeli-headquartered business has grown into a global leader with a dual focus on generic pharmaceuticals and a focused portfolio of branded specialty medicines.

Generic & Biosimilar Scale

Teva's generics business underpins the company's identity. Its manufacturing network produces a vast range of solid oral doses, injectables, and respiratory products, serving retail pharmacies, hospital systems, and government procurement agencies worldwide. The company has also built a growing biosimilars division, seeking to bring lower-cost biological medicines to patients in oncology, immunology, and other high-cost therapy areas as reference products lose patent protection.

Branded Specialty: AUSTEDO and Neurology

On the branded side, Teva's most significant commercial asset is AUSTEDO (deutetrabenazine), approved for tardive dyskinesia and Huntington's disease chorea, and one of the company's primary revenue growth drivers in recent years. The company also markets AJOVY (fremanezumab), a calcitonin gene-related peptide inhibitor for migraine prevention, reflecting a sustained commitment to central nervous system disorders. Teva's respiratory franchise, built in part around the ProAir and QVAR brands, further diversifies its branded presence.

Teva trades on the New York Stock Exchange under the ticker TEVA and on the Tel Aviv Stock Exchange, giving it a dual-listed profile unusual among its peers. Headquarters are in Tel Aviv, Israel, with major operational hubs across the United States, Europe, and Israel. The company has faced significant financial restructuring over the past decade following its 2016 acquisition of Allergan's generics business, and has pursued a multi-year transformation plan centred on debt reduction and portfolio rationalisation.

Further information is available at tevapharm.com.

Similar Companies

More in Neuroscience & CNS

B

Biogen

Biogen pioneered the neuroscience field as one of the world's oldest independent biotechnology companies, founded in 1978 by a group of distinguished scientists including Nobel laureate Walter Gilbert. Headquartered in Cambridge, Massachusetts, the company has spent nearly five decades focused almost exclusively on neurological and neurodegenerative diseases, a level of specialisation that sets it apart from diversified pharma peers. Neuroscience Focus and Key Therapy Areas Biogen's portfolio centres on multiple sclerosis, where it holds one of the broadest treatment ranges in the industry, spanning injectable, oral, and infusion therapies. The company also works in spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. Its partnership with Eisai produced lecanemab (marketed as Leqembi), an Alzheimer's treatment that received traditional FDA approval in 2023, marking a significant moment in a field that had seen decades of clinical setbacks. Global Scale and Commercial Presence Listed on the Nasdaq under the ticker BIIB, Biogen operates across more than 30 countries, with commercial infrastructure spanning North America, Europe, and Asia Pacific. The company invests heavily in research and development as a proportion of revenue, consistent with its identity as a science-led organisation rather than a marketing-driven one. Its biosimilars division, built through a long-standing collaboration with Samsung Bioepis, gives Biogen a commercial presence in the cost-sensitive biologics market alongside its branded neurology pipeline. Biogen has also expanded into rare disease and neuropsychiatry, reflecting a strategic effort to broaden the neuroscience platform beyond multiple sclerosis as the MS market faces increasing genericisation. The company's gene therapy interests, including assets in-licensed and acquired over recent years, signal further ambition in treating diseases at the molecular level. For professionals in pharmaceutical, biotech, and medical research sectors, Biogen represents one of the most focused large-cap neuroscience organisations operating globally. Further information is available at biogen.com.

View profile
W

Worldwide Clinical Trials

Operating across more than 60 countries, Worldwide Clinical Trials is a full-service contract research organisation built around a single discipline: clinical development. Founded in 1986, the company has spent nearly four decades focusing exclusively on Phase I through Phase IV studies, giving it a depth of therapeutic and regulatory expertise that generalist CROs rarely match. The organisation is particularly well regarded for its work in central nervous system research, where it operates dedicated CNS units with specialist investigators and patient populations. Alongside CNS, Worldwide Clinical Trials carries strong capabilities in cardiovascular, metabolic, and rare disease development, areas where patient recruitment complexity and protocol design demand experienced hands. Its Phase I infrastructure includes purpose-built clinical pharmacology units that support first-in-human studies, bioavailability and bioequivalence work, and early proof-of-concept programmes. This early-phase foundation connects seamlessly into its late-phase trial management, allowing sponsors to maintain a single CRO relationship from initial dosing through to regulatory submission. Worldwide Clinical Trials works primarily with mid-size and emerging biopharmaceutical companies, positioning itself as a committed partner rather than a high-volume processor. That focus has earned it a reputation for therapeutic expertise and operational flexibility, qualities that sponsors managing complex or novel compounds tend to prioritise. Headquarters are in Wayne, Pennsylvania, with a global network of offices and clinical sites spanning North America, Europe, and beyond. Further information is available at worldwide.com.

View profile
R

Roche

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology, haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy